FR561M - - Google Patents

Info

Publication number
FR561M
FR561M FR836271A FR836271A FR561M FR 561 M FR561 M FR 561M FR 836271 A FR836271 A FR 836271A FR 836271 A FR836271 A FR 836271A FR 561 M FR561 M FR 561M
Authority
FR
France
Prior art keywords
dextran
benzyl
pharmaceutical product
chloride
substituted
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
FR836271A
Other languages
French (fr)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Application granted granted Critical
Publication of FR561M publication Critical patent/FR561M/fr
Active legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/429—Thiazoles condensed with heterocyclic ring systems
    • A61K31/43—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/58—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. poly[meth]acrylate, polyacrylamide, polystyrene, polyvinylpyrrolidone, polyvinylalcohol or polystyrene sulfonic acid resin
    • A61K47/585—Ion exchange resins, e.g. polystyrene sulfonic acid resin
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/0006—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid
    • C08B37/0009—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid alpha-D-Glucans, e.g. polydextrose, alternan, glycogen; (alpha-1,4)(alpha-1,6)-D-Glucans; (alpha-1,3)(alpha-1,4)-D-Glucans, e.g. isolichenan or nigeran; (alpha-1,4)-D-Glucans; (alpha-1,3)-D-Glucans, e.g. pseudonigeran; Derivatives thereof
    • C08B37/0021—Dextran, i.e. (alpha-1,4)-D-glucan; Derivatives thereof, e.g. Sephadex, i.e. crosslinked dextran

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Materials Engineering (AREA)
  • Biochemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Polymers & Plastics (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

A sustained release pharmaceutical product comprises a medicinally-active substance in combination with a carboxy alkyl benzyl dextran. The dextran derivative is preferably a carboxymethyl benzyl dextran having a high benzyl degree of substitution (D.S) and a relatively low carboxyl D.S. obtained by treating dextran in water at 40 DEG C. with sodium monochloroacetate and subsequently with benzyl chloride using a ratio of 3:1 to 6:1 of the chloride to the substituted dextran. It may be used in a proportion between 1 and 50% by weight of the pharmaceutical product. Medicaments which may be combined with the substituted dextran are amphetamine hydrochloride, penicillin, streptomycin, chloroprophenyridamine, meperidine, codeine, ephedrine, quinine, quinidine, nicotine, cinchonidine, apmorphine, strychnine, scopolamine or atropine. Inert fillers such as terra alba and starch; and antihistamines, barbiturates, glycols, soya bean oil, sesame oil, hydrogenated peanut oil and a mixture of oils with beeswax may also be added. The pharmaceutical product may be used as a dry powder or mixed with liquids to form pastes or wax-like masses, compressed into tablets, pills or pellets or packaged into dry-filled or soft elastic capsules, or sealed into ampoules, or administered in liquid form by intravenous, intramuscular, sublingual, subcutaneous, rectal, intraspinous or intrathecal injection or infused into the vaginal or urinary tract.ALSO:A sustained release pharmaceutical product comprises a medicinally-active substance in combination with a carboxy alkyl benzyl dextran. The dextran derivative is preferably a carboxymethyl benzyl dextran having a high benzyl degree of substitution (D.S.) and a relatively low carboxyl D.S. obtained by treating dextran in water at 40 DEG C. with sodium monochloroacetate and subsequently with benzyl chloride using a ratio of 3:1 to 6:1 of the chloride to the substituted dextran. It may be used in a proportion between 1 and 50% by weight of the pharmaceutical product. Medicaments which may be combined with the substituted dextran include penicillin and streptomycin, which form salts with the dextran derivative.ALSO:A sustained release pharmaceutical product comprises a medicinally-active substance in combination with a carboxy alkyl benzyl dextran. The destran derivative is preferably a carboxymethyl benzyl dextran having a high benzyl degree of substitution (D.S.) and a relatively low carboxyl D.S. obtained by treating dextran in water at 40 DEG C. with sodium monochloroacetate and subsequently with benzyl chloride using a ratio of 3 : 1 to 6 : 1 of the chloride to the substituted dextran. It may be used in a proportion between 1 and 50% by weight of the pharmaceutical product. Medicaments which may be combined with the substituted dextran are amphetamine hydrochloride penicillin, streptomycin, chloroprophenyridamine, meperidine, codeine, ephedrine, quinine, quinidine, nicotine, cinchonidine, apomorphine, strychnine, scopolamine or atropine. Inert fillers such as terra alba and starch; and antihistamines, barbiturates, glycols, soya bean oil, sesame oil, hydrogenated peanut oil and a mixture of oils with beeswax may also be added. The pharmaceutical product may be used as a dry powder or mixed with liquids to form pastes or wax-like masses, compressed into tablets, pills or pellets or packaged into dry-filled or soft elastic capsules, or sealed into ampoules, or administered in liquid form by intravenous, intramuscular, sublingual, subcutaneous, rectal, intraspinous or intrathecal injection or infused into the vaginal or urinary tract.
FR836271A 1959-08-21 1960-08-19 Active FR561M (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US835189A US3063905A (en) 1959-08-21 1959-08-21 Carboxy methyl benzyl dextran dextro-amphetamine

Publications (1)

Publication Number Publication Date
FR561M true FR561M (en) 1961-06-05

Family

ID=25268864

Family Applications (1)

Application Number Title Priority Date Filing Date
FR836271A Active FR561M (en) 1959-08-21 1960-08-19

Country Status (6)

Country Link
US (1) US3063905A (en)
BE (1) BE594311A (en)
DE (1) DE1177773B (en)
FR (1) FR561M (en)
GB (1) GB904874A (en)
NL (1) NL255047A (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2484838A1 (en) * 1980-06-20 1981-12-24 Crinos Industria Farmaco VEHICLES FOR SPERMICIDAL SUBSTANCES

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3130125A (en) * 1962-09-14 1964-04-21 Central Pharmacal Company Preparation of medicated benzyl dextran gradual release therapeutic products containing up to five percent benzyl alcohol
US3130126A (en) * 1962-09-14 1964-04-21 Central Pharmacal Company Oral pharmaceutical products prepared with carboxymethyl benzyl dextran having a low carboxymethyl d. s. of 0.15
US3242049A (en) * 1963-05-20 1966-03-22 Ncr Co Process for making enterically useful complex of spiramycin and product thereof
US3364111A (en) * 1964-11-20 1968-01-16 Meito Sangyo Kk Carboxymethylated dextran for peptic ulcers
US4260602A (en) * 1977-08-16 1981-04-07 Burroughs Wellcome Co. Hapten polysaccharide conjugate medicaments and method of use
SE445013B (en) * 1979-06-21 1986-05-26 Landstingens Inkopscentral Means for preventing or treating infections by humans and animals
DE3332429T1 (en) * 1982-02-22 1984-01-26 Belorusskij naučno-issledovatel'skij sanitarno-gigieničeskij institut, 220012 Minsk MEDICINAL PRODUCT WITH ANTINICOTINE EFFECT AND METHOD FOR THE PRODUCTION THEREOF
GB9614902D0 (en) * 1996-07-16 1996-09-04 Rhodes John Sustained release composition
US20110076332A1 (en) * 2009-08-27 2011-03-31 Xiaojun Yu Dextran-chitosan based in-situ gelling hydrogels for biomedical applications

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2536168A (en) * 1947-09-29 1951-01-02 Clark & Clark Co Amphetamine chewing gum
US2609368A (en) * 1950-10-21 1952-09-02 Univ Ohio State Res Found Carbohydrate processes
US2749274A (en) * 1952-05-06 1956-06-05 Bristol Lab Inc Stable aqueous procaine penicillin suspension
BE550150A (en) * 1955-08-08
US2811516A (en) * 1955-09-21 1957-10-29 Ohio Commw Eng Co Iodo carboxymethyl dextran and methods of making it
US2885393A (en) * 1956-02-24 1959-05-05 R K Laros Company Dextran-iron complex and process for making same
US2856398A (en) * 1956-06-15 1958-10-14 Ohio Commw Eng Co Carboxymethyl dextran-iron complexes
US2902408A (en) * 1957-09-12 1959-09-01 Organon Suspensions of drugs destined for injection and process for the preparation thereof
US2997423A (en) * 1959-04-20 1961-08-22 Ohio Commw Eng Co Method of making a composition of sodium carboxymethyl dextran and an antibiotic

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2484838A1 (en) * 1980-06-20 1981-12-24 Crinos Industria Farmaco VEHICLES FOR SPERMICIDAL SUBSTANCES

Also Published As

Publication number Publication date
GB904874A (en) 1962-09-05
NL255047A (en)
US3063905A (en) 1962-11-13
BE594311A (en) 1961-02-22
DE1177773B (en) 1964-09-10

Similar Documents

Publication Publication Date Title
KR940008030B1 (en) Solvent system for an ionizable pharmaceutical agent
EP0185420B1 (en) Dihydrocodeine/ibuprofen pharmaceutical compositions and method
FR561M (en)
US4778799A (en) Synergistic combination of flupirtin and non-steroidal antiphlogistic
US3143465A (en) Pharmaceutical preparations comprising phosphorus containing cation exchange resins having a basic drug adsorbed thereon; and treatment therewith
DE2966564D1 (en) Therapeutic compositions with enhanced bioavailability and process for their preparation
ES8506705A1 (en) 3-(1-Substituted-4-piperidyl)-1,2-benzisoxazoles, a process for the preparation thereof, a pharmaceutical composition comprising the same, and their use as medicaments.
GB902659A (en) A process for the production of a derivative of thebaine
US2910403A (en) Anti hypertensive compositions comprising 2-methyl-5, 8-dimethoxychromone and acetamides
ES449062A1 (en) Pharmaceutical compositions
US3181994A (en) Analgesic biphenyl acetic acid derivatives
US2472453A (en) Streptomycin composition of reduced toxicity
US2224256A (en) Pharmaceutical preparation
US3019166A (en) Antiphlogistic and choleretic compositions and process of therapeutically using same
ES269442A1 (en) Lysine orotate
US3262847A (en) Calcium salt of dextran for treating cattle delivery paresis
US3644630A (en) Indomethacin suppositories
US2940898A (en) Aluminum salt antacid compositions and method of using same
US2907768A (en) Dihydrohydroxycodeinone derivative
US3298915A (en) Vascular headache treatment
GB808269A (en) Barbiturate pharmaceutical preparations
GB1505849A (en) 9,10-dihydroanthracen-9,10-imine derivatives
US3686409A (en) Combination of l-dopa and 2-imino-5-phenyl-4-oxazolidinone used to treat parkinson{40 s disease
US3743732A (en) Process for suppressing the tremor of parkinson's syndrome
IL42201A (en) 2-((1-benzylcyclopentyl)-imino)pyrrolidine